Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SnowShredder who wrote (28)	1/13/2002 12:12:12 AM
From: SnowShredder	Read Replies (2) of 253

Just parking...Best of luck, SS >>> intronn.com Intronn has developed and patented a new technology for gene therapy that exploits the differential gene expression between normal and diseased cells. It is called Spliceosome Mediated RNA Trans-splicing Gene Therapy or SMaRT Gene Therapy. This technology may be applied to a wide range of diseases that involve the expression of unique or mutated genes. By using SMaRT Gene Therapy, virtually any gene (pre-mRNA) may be targeted and reprogrammed to produce a new gene product useful in treating that disease. SMaRT technology can be employed to control the expression of any delivered gene by the presence of the chosen target pre-mRNA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next